Suppr超能文献

突触足蛋白-2通过抑制YAP/TAZ活性抑制三阴性乳腺癌的转移。

Synaptopodin-2 suppresses metastasis of triple-negative breast cancer via inhibition of YAP/TAZ activity.

作者信息

Liu Junling, Ye Liping, Li Qingyuan, Wu Xianqiu, Wang Bin, Ouyang Ying, Yuan Zhongyu, Li Jun, Lin Chuyong

机构信息

Sun Yat-sen University Cancer Centre, State Key Laboratory of Oncology in Southern China, Collaborative Innovation Centre for Cancer Medicine, Guangzhou, PR China.

Guangdong Country Garden School, Shunde, Foshan, Guangdong, PR China.

出版信息

J Pathol. 2018 Jan;244(1):71-83. doi: 10.1002/path.4995.

Abstract

Triple-negative breast cancer (TNBC) represents the most aggressive subtype of breast cancer, with a high incidence of distant metastasis; however, the underlying mechanism for this frequent recurrence remains unclear. Herein, we show that synaptopodin-2 (SYNPO2), a putative tumour suppressor in aggressive cancer, is frequently downregulated in TNBC by methylation of the promoter of SYNPO2. Low expression levels of SYNPO2 correlated significantly with 5-year metastatic relapse, and predicted poorer prognosis in breast cancer patients. Reintroduction of SYNPO2 inhibited the invasion and spontaneous metastasis of TNBC cells in vivo. Strikingly, downregulation of SYNPO2 is essential for the maintenance of stem cell-like properties in TNBC cells, leading to efficient distant colonization and metastasis outgrowth. Moreover, we demonstrate that SYNPO2 inhibits the activities of YAP and TAZ by stabilizing LATS2 protein, and transduction of YAP-S127A abrogates the repressive role of SYNPO2 in metastasis. Finally, immunohistochemical (IHC) analysis of breast cancer patient specimens indicated that the SYNPO2-LATS2-YAP axis is clinically relevant. These findings uncover a suppressive role of SYNPO2 in TNBC metastasis via inhibition of YAP/TAZ, and suggest that SYNPO2 might provide a potential prognosis marker and novel therapeutic strategy. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

摘要

三阴性乳腺癌(TNBC)是乳腺癌中最具侵袭性的亚型,远处转移发生率高;然而,这种频繁复发的潜在机制仍不清楚。在此,我们表明,突触足蛋白-2(SYNPO2)是侵袭性癌症中的一种假定肿瘤抑制因子,在TNBC中常因SYNPO2启动子甲基化而下调。SYNPO2低表达水平与5年转移性复发显著相关,并预示着乳腺癌患者预后较差。重新引入SYNPO2可抑制TNBC细胞在体内的侵袭和自发转移。引人注目的是,SYNPO2的下调对于维持TNBC细胞中的干细胞样特性至关重要,从而导致有效的远处定植和转移生长。此外,我们证明SYNPO2通过稳定LATS2蛋白来抑制YAP和TAZ的活性,并且YAP-S127A的转导消除了SYNPO2在转移中的抑制作用。最后,对乳腺癌患者标本的免疫组织化学(IHC)分析表明,SYNPO2-LATS2-YAP轴具有临床相关性。这些发现揭示了SYNPO2通过抑制YAP/TAZ在TNBC转移中的抑制作用,并表明SYNPO2可能提供一种潜在的预后标志物和新的治疗策略。版权所有©2017英国和爱尔兰病理学会。由约翰·威利父子有限公司出版。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验